论文部分内容阅读
观察口服选择性白三烯D_4(LTD_4)受体拮抗剂ICI 204219对运动性哮喘(EIA)的抑制效应,探讨LT在EIA中的作用。方法研究对象为8例男性不吸烟的稳定期哮喘患者,其中7例属特应性体质。采用安慰剂双盲对照、随机交叉研究。运动试验在电动踏车上进行,2次试验相隔1周。停用支气管扩张剂及可的松类吸入剂,休息5min后测定FEV_1,给予20mg ICI 204219或相似安慰剂药片,2h后测定运动前FEV_1,然后按预定标准(踏车速度及梯度使FEV_1较试验前减低25％以
To observe the inhibitory effect of oral selective leukotriene D_4 (LTD_4) receptor antagonist ICI 204219 on exercise-induced asthma (EIA) and to explore the role of LT in EIA. METHODS: Eight stable patients with stable asthma who did not smoke were included in the study. Seven of them were atopic. Placebo double-blind control, randomized crossover study. Exercise test on the electric treadmill, two tests separated by 1 week. Bronchodilators and cortisone inhalers were discontinued, FEV_1 was measured after a 5-minute rest, and 20 mg of ICI 204219 or placebo tablets were given after 2 hours. Pre-exercise FEV_1 was measured after 2 hours and then compared with a predetermined standard (treadmill speed and gradient FEV_1 test Decreased by 25% before